Skip to main content
HARBIN GLORIA PHARMACEUTICALS Co., LTD logo

HARBIN GLORIA PHARMACEUTICALS Co., LTD — Investor Relations & Filings

Ticker · 002437 ISIN · CNE100000QG8 LEI · 300300K1ZDAXM6M73U33 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,133 across all filing types
Latest filing 2024-04-19 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002437

About HARBIN GLORIA PHARMACEUTICALS Co., LTD

https://www.gloria.cc

Harbin Gloria Pharmaceuticals Co., Ltd. focuses on the research, development, manufacturing, and commercialization of diverse pharmaceutical products. The company specializes in therapeutic areas including cardiovascular and cerebrovascular diseases, orthopedics, oncology, and metabolic disorders. Its portfolio comprises chemical drugs, biological products, and specialized injections, with key products such as Alprostadil and Deer Melon Polypeptide. The organization prioritizes technological innovation through a dedicated R&D infrastructure aimed at developing both generic and innovative medications. It maintains multiple production facilities and an extensive distribution network to supply healthcare solutions for chronic and acute conditions.

Recent filings

Filing Released Lang Actions
关于公司独立董事、副总经理辞职的公告
Board/Management Information Classification · 100% confidence The document is a company announcement regarding the resignation of an independent director and a deputy general manager. It details the reasons for resignation, the impact on board composition, and the effective dates of resignation. There is no financial data, no mention of annual or quarterly reports, no audit information, no voting results, and no other report types. The content clearly relates to changes in the company's board and senior management. The document length is short (1004 characters), consistent with a management or board change announcement. Therefore, the appropriate classification is Board/Management Information (MANG).
2024-04-19 Chinese
2024年第一季度业绩预告
Earnings Release Classification · 95% confidence The document is titled as a "2024 年第一季度业绩预告" which translates to "2024 First Quarter Earnings Forecast." It provides estimated financial results for the first quarter of 2024, including expected net profit and earnings per share, along with explanations for changes and risk warnings. The document explicitly states that the financial data are preliminary estimates and that the actual detailed financial data will be disclosed in the official 2024 first quarter report. The document length is short (1237 characters), and it does not contain actual financial statements or detailed financial analysis, only forecasts and preliminary estimates. Therefore, it is not a full Interim/Quarterly Report (IR) but rather an Earnings Release (ER) type document announcing preliminary quarterly results. Q1 2024
2024-04-12 Chinese
2023年度业绩快报暨2023年度业绩预告修正公告
Earnings Release Classification · 95% confidence The document is titled as a "2023年度业绩快报暨2023年度业绩预告修正公告" which translates to "2023 Annual Performance Express Report and 2023 Annual Performance Forecast Revision Announcement." It contains key financial data for the full year 2023, including revenue, profit, net income, earnings per share, and asset information. The document also discusses reasons for changes in financial results, differences from previous forecasts, and risk warnings. It explicitly states that the financial data has been preliminarily audited by the company's auditor and that the final results will be in the 2023 Annual Report. The document length is about 2596 characters, which is relatively short and more consistent with a performance summary or earnings release rather than a full annual report. The document is not a full annual report (10-K) because it lacks comprehensive financial statements and detailed disclosures. It is not a report publication announcement because it contains substantive financial data and explanations, not just a notice of report availability. The document is essentially an earnings release for the full year 2023 with a revision to prior earnings guidance. Therefore, the best classification is Earnings Release (ER). FY 2023
2024-04-12 Chinese
关于2024年限制性股票激励计划首次授予登记完成的公告
Share Issue/Capital Change Classification · 95% confidence The document is a detailed announcement regarding the completion of the first grant registration under the company's 2024 restricted stock incentive plan. It includes specifics such as grant dates, number of shares granted, pricing, approval procedures, performance assessment criteria, stock lock-up periods, and the impact on the company's capital structure and financials. It also references legal opinions, board and supervisory committee approvals, and an audit report related to the capital verification. The document is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a simple announcement of a report publication. It is not a transcript, earnings release, or a regulatory filing of a different nature. The content focuses on management decisions and disclosures about stock incentives and related capital changes, which aligns with announcements about share issues or capital changes. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA). The document length (7679 characters) and detailed content confirm it is a substantive announcement, not a brief notice or certification.
2024-03-10 Chinese
2024年限制性股票激励计划调整及首次授予事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the adjustment and initial grant of a 2024 restricted stock incentive plan for Harbin Yuheng Pharmaceutical Co., Ltd. It details the legal compliance, approval procedures, grant conditions, and other legal verifications related to the stock incentive plan. The document is not a financial report, earnings release, or regulatory announcement but a legal opinion on a specific corporate action related to stock incentives. This type of document does not fit into categories like Annual Report, Earnings Release, or Capital/Financing Update. It is a specialized legal opinion related to management and governance matters concerning stock incentives. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a regulatory legal document that does not fit other specific categories.
2024-02-05 Chinese
关于向激励对象授予限制性股票的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Harbin Yuheng Pharmaceutical Co., Ltd. regarding the granting of restricted stocks to incentive recipients under a 2024 restricted stock incentive plan. It includes specifics such as the number of shares granted, grant price, allocation among recipients, vesting and lock-up periods, performance assessment criteria, approval procedures, and legal opinions. The content focuses on the issuance of shares to management and key personnel as part of an equity incentive plan. This type of document is a formal announcement about a share-based compensation plan and the related share issuance, which fits the category of Capital/Financing Update (CAP) because it involves changes in the company's capital structure through issuance of restricted shares to employees and management. It is not a full financial report, audit report, or management discussion, nor is it a regulatory filing or proxy material. The document length and detail confirm it is not a brief announcement or a report publication notice. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-02-05 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.